Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CEO Sells $1,435,000.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $71.75, for a total value of $1,435,000.00. Following the completion of the sale, the chief executive officer owned 767,780 shares in the company, valued at $55,088,215. This represents a 2.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Wednesday, May 13th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.19, for a total value of $691,900.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $63.50, for a total value of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total value of $1,284,800.00.
• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $70.21, for a total value of $702,100.00.
• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $1,393,800.00.

Halozyme Therapeutics Price Performance

HALO stock opened at $67.12 on Friday. The company has a current ratio of 2.76, a quick ratio of 3.66 and a debt-to-equity ratio of 8.81. The company has a market capitalization of $7.96 billion, a PE ratio of 24.14, a P/E/G ratio of 0.28 and a beta of 0.89. Halozyme Therapeutics, Inc. has a 12-month low of $48.64 and a 12-month high of $82.22. The business’s fifty day moving average price is $65.65 and its 200 day moving average price is $68.64.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The company’s quarterly revenue was up 42.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. On average, sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 7.66 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Root Financial Partners LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter worth $25,000. Larson Financial Group LLC grew its stake in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Measured Wealth Private Client Group LLC grew its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares in the last quarter. Richardson Financial Services Inc. grew its stake in Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 198 shares in the last quarter. Finally, Clearstead Advisors LLC grew its stake in Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares in the last quarter. 97.79% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently issued reports on HALO. Benchmark boosted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday. Wall Street Zen upgraded Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. HC Wainwright boosted their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Finally, Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Seven research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $80.67.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.